Closely Watched Mirati Reveals Results to Rival Amgen Drug

(Bloomberg) — Mirati Therapeutics Inc., one of the most talked-about names in biotech and a frequenter of Wall Street’s M&A shopping lists, released drug-trial results that set a higher bar against a competitor drug from biotech behemoth Amgen Inc. The experimental drug, known as adagrasib, or MRTX849, produced responses in 45% of lung cancer patients in an early stages of study. That’s better than some of the results from Amgen’s sotorasib….